FDA approves Jetrea (Thrombogenics NV) for the treatment of Vitreomacular Adhesion

The FDA has approved Jetrea (ocriplasmin), from Thrombogenics NV, in the US for the treatment of symptomatic Vitreomacular Adhesion (VMA), a progressive sight threatening condition. Jetrea is the first pharmacological agent to be approved for this indication. The approval was based on the data from ThromboGenics' Phase III program where Jetrea was shown to be superior to placebo for the treatment of symptomatic VMA (26.5% versus 10.1%; p<0.01). treatment with jetrea was associated with some mainly transient ocular adverse events. the drug was filed with the ema in march 2012 and is now under review.>